Abstract

AbstractLooking back on the development of radiomics in osteosarcoma over recent years, in addition to distinguishing osteosarcoma from other malignant bone tumors (mainly Ewing's sarcoma), more research directions are using radiomics to evaluate and predict the efficacy and survival of patients undergoing neoadjuvant chemotherapy. Among the three commonly used examination methods of X‐ray, CT, and magnetic resonance imaging (MRI), more and more studies have been conducted on MRI‐based radiomics, which fully reflects the advantages of MRI's high soft tissue contrast, multi‐sequence imaging, and most of the studies used a combination of imaging features and clinical features to make predictions. Some articles also considered relevant laboratory examination results and more and more studies are performing external verification. The field is now gradually developing toward multidimensional data and multicenter cooperation and data sharing.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.